In one of the earlier studies, intradermal immunization with a peptide vaccine based on HER2/neu combined with granulocyte macrophage colony stimulating factor (GM-CSF) as an adjuvant induced CD4+ T helper-specific immunological response in patients with breast and ovarian cancer. Here, ERBB2 is linked to ovarian carcinoma.